PMC:2812702 / 1683-2551 JSONTXT

{"project":"MyTest","denotations":[{"id":"19837460-16502872-27808535","span":{"begin":390,"end":391},"obj":"16502872"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Such doubts about receptors were only dispelled with the development of the first receptor-specific remedies, in particular the beta-receptor blockers for the therapy of hypertension and the histamine-H2-receptor blockers for the treatment of stomach ulcers. James Black, who was the originator of both these groups of drugs, was awarded the Nobel Prize for Medicine or Physiology in 1988 [3]. By this time other researchers had elucidated the protein structure and genetic basis of various other receptors and had even visualised some of them with electron microscopy. It became increasingly clear that the human body contained many hundreds of receptor subtypes, opening up a vast new field of research to the pharmaceutical industry. The aim was to target these receptors for the specific treatment of various diseases, ranging from cystic fibrosis to epilepsy [4]."}

{"project":"2_test","denotations":[{"id":"19837460-16502872-27808535","span":{"begin":390,"end":391},"obj":"16502872"}],"text":"Such doubts about receptors were only dispelled with the development of the first receptor-specific remedies, in particular the beta-receptor blockers for the therapy of hypertension and the histamine-H2-receptor blockers for the treatment of stomach ulcers. James Black, who was the originator of both these groups of drugs, was awarded the Nobel Prize for Medicine or Physiology in 1988 [3]. By this time other researchers had elucidated the protein structure and genetic basis of various other receptors and had even visualised some of them with electron microscopy. It became increasingly clear that the human body contained many hundreds of receptor subtypes, opening up a vast new field of research to the pharmaceutical industry. The aim was to target these receptors for the specific treatment of various diseases, ranging from cystic fibrosis to epilepsy [4]."}